Isocitrate Dehydrogenase (IDH)

AGI-12026 is a brain-penetrant dual inhibitor targeting mutant isocitrate dehydrogenase 1 and 2 (IDH1/2). It acts as an allosteric modulator, demonstrating partial inhibition of the IDH1-R132H homodimer. This compound is suitable for research applications related to glioma and provides a valuable tool for studying the role of mutant IDH enzymes in cancer biology.

(R)-IDHP is an isomer of isovaleryl-DL-3-hydroxybutyric acid, functioning primarily by inhibiting Ca2+ release and modulating Ca2+ inward flow in both voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. This compound exhibits vasorelaxant properties and is valuable in research focused on cardiovascular disease mechanisms and treatments. Its biological activity makes it a useful tool for investigating vascular dynamics and related pathophysiological conditions.

Enasidenib mesylate is a selective inhibitor of mutant isocitrate dehydrogenase 2 (IDH2) enzymes, demonstrating potent and reversible binding. It primarily exerts its biological activity by altering the metabolism of 2-hydroxyglutarate, thus affecting cellular processes associated with cancer progression. This compound is utilized in research focused on hematologic malignancies, particularly those driven by IDH2 mutations.